These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 24618388)

  • 1. Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.
    Proskorovsky I; Lewis P; Williams CD; Jordan K; Kyriakou C; Ishak J; Davies FE
    Health Qual Life Outcomes; 2014 Mar; 12():35. PubMed ID: 24618388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial.
    Delforge M; Patel K; Eliason L; Dhanda D; Shi L; Guo S; Marshall TS; Arnulf B; Cavo M; Nooka A; Manier S; Callander N; Giralt S; Einsele H; Ailawadhi S; Popa McKiver M; Cook M; Rodríguez-Otero P
    Lancet Haematol; 2024 Mar; 11(3):e216-e227. PubMed ID: 38423700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model.
    Franken MD; de Hond A; Degeling K; Punt CJA; Koopman M; Uyl-de Groot CA; Versteegh MM; van Oijen MGH
    Health Qual Life Outcomes; 2020 Jul; 18(1):240. PubMed ID: 32690011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mapping EORTC QLQ-C30 and FACT-G onto EQ-5D-5L index for patients with cancer.
    Hagiwara Y; Shiroiwa T; Taira N; Kawahara T; Konomura K; Noto S; Fukuda T; Shimozuma K
    Health Qual Life Outcomes; 2020 Nov; 18(1):354. PubMed ID: 33143687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of Bayesian Markov chain Monte Carlo methods to estimate EQ-5D utility scores from EORTC QLQ data in myeloma for use in cost-effectiveness analysis.
    Kharroubi SA; Edlin R; Meads D; Browne C; Brown J; McCabe C
    Med Decis Making; 2015 Apr; 35(3):351-60. PubMed ID: 25784746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments.
    Kontodimopoulos N; Aletras VH; Paliouras D; Niakas D
    Value Health; 2009; 12(8):1151-7. PubMed ID: 19558372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of generic, condition-specific, and mapped health state utility values for multiple myeloma cancer.
    Rowen D; Young T; Brazier J; Gaugris S
    Value Health; 2012 Dec; 15(8):1059-68. PubMed ID: 23244808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian statistical models to estimate EQ-5D utility scores from EORTC QLQ data in myeloma.
    Kharroubi SA; Edlin R; Meads D; McCabe C
    Pharm Stat; 2018 Jul; 17(4):358-371. PubMed ID: 29460413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mapping EORTC-QLQ-C30 and QLQ-CR29 onto EQ-5D-5L in Colorectal Cancer Patients.
    Ameri H; Yousefi M; Yaseri M; Nahvijou A; Arab M; Akbari Sari A
    J Gastrointest Cancer; 2020 Mar; 51(1):196-203. PubMed ID: 30977049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reliability and Validity of an Iranian Version of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Patients with Multiple Myeloma: the EORTC QLQ-MY20.
    Ahmadzadeh A; Yekaninejad MS; Saffari M; Pakpour AH; Aaronson NK
    Asian Pac J Cancer Prev; 2016; 17(1):255-9. PubMed ID: 26838220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mapping EORTC QLQ-C30 onto EQ-5D for the assessment of cancer patients.
    Kim SH; Jo MW; Kim HJ; Ahn JH
    Health Qual Life Outcomes; 2012 Dec; 10():151. PubMed ID: 23244763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mapping the EORTC QLQ-C30 and QLQ-H&N35, onto EQ-5D-5L and HUI-3 indices in patients with head and neck cancer.
    Noel CW; Stephens RF; Su JS; Xu W; Krahn M; Monteiro E; Goldstein DP; Giuliani M; Hansen AR; de Almeida JR
    Head Neck; 2020 Sep; 42(9):2277-2286. PubMed ID: 32333829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mapping EORTC-QLQ-C30 to EQ-5D-3L in patients with colorectal cancer.
    Marriott ER; van Hazel G; Gibbs P; Hatswell AJ
    J Med Econ; 2017 Feb; 20(2):193-199. PubMed ID: 27676291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An assessment of the external validity of mapping QLQ-C30 to EQ-5D preferences.
    Crott R; Versteegh M; Uyl-de-Groot C
    Qual Life Res; 2013 Jun; 22(5):1045-54. PubMed ID: 22743734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mapping the EORTC QLQ-C30 to EQ-5D-3L in patients with breast cancer.
    Gray LA; Hernandez Alava M; Wailoo AJ
    BMC Cancer; 2021 Nov; 21(1):1237. PubMed ID: 34794404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testing mapping algorithms of the cancer-specific EORTC QLQ-C30 onto EQ-5D in malignant mesothelioma.
    Arnold DT; Rowen D; Versteegh MM; Morley A; Hooper CE; Maskell NA
    Health Qual Life Outcomes; 2015 Jan; 13():6. PubMed ID: 25613110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mapping the Chinese Version of the EORTC QLQ-BR53 Onto the EQ-5D-5L and SF-6D Utility Scores.
    Liu T; Li S; Wang M; Sun Q; Chen G
    Patient; 2020 Oct; 13(5):537-555. PubMed ID: 32382953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indirect and Direct Mapping of the Cancer-Specific EORTC QLQ-C30 onto EQ-5D-5L Utility Scores.
    Meunier A; Soare A; Chevrou-Severac H; Myren KJ; Murata T; Longworth L
    Appl Health Econ Health Policy; 2022 Jan; 20(1):119-131. PubMed ID: 34554442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mapping EORTC-QLQ-C30 onto EQ-5D-5L Index in Indonesian Cancer Patients.
    Perwitasari DA; Purba FD; Candradewi SF; Marwin M; Permata A; Ulfa Faza MB; Septiantoro BP; Kaptein AA
    Asian Pac J Cancer Prev; 2023 Apr; 24(4):1125-1130. PubMed ID: 37116132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimating the minimally important difference for the EQ-5D-5L and EORTC QLQ-C30 in cancer.
    Bourke S; Bennett B; Oluboyede Y; Li T; Longworth L; O'Sullivan SB; Braverman J; Soare IA; Shaw JW
    Health Qual Life Outcomes; 2024 Sep; 22(1):81. PubMed ID: 39304893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.